Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $173

Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price target from $160 to $173.

Benzinga · 12/24/2019 13:13

Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price target from $160 to $173.